Investment Review day 3 of 50: Guardant Health $GH
Guardant Health is at the forefront of liquid biopsy innovation. Their blood tests enable early cancer detection via the analysis of circulating tumor DNA. This has the potential to revolutionize patient outcomes.
Guardant is a key holding in my healthcare portfolio, I bought stock in 2019 and again in 2020. The market for liquid biopsy is rapidly growing, but it’s also intensely competitive. Regulatory hurdles and reimbursement issues remain challenges. The long-term outlook is promising, yet uncertain.
Which medtech companies do you own?
—
I’m putting my holdings under the microscope. Over the next 50 days I’ll break down my whole investment portfolio. Wins, losses, and the ‘why’ behind it all. And on day 50 I’m going to share the full portfolio! Follow me and let’s learn together! #StockAnalysis #50daychallenge #investing #liquidbiopsy #cancerdetection
